RA0520

antibody from Oursmab

Targeting: NCAM1 CD56, NCAM

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0520

Provider

Oursmab

Product name

Lorvotuzumab (Biosimilar Reference Antibody) (NCAM1)

Antibody type

Monoclonal

Description

Lorvotuzumab (also known as huN901) is a humanized monoclonal antibody that targets CD56 (neural cell adhesion molecule, NCAM), a cell-surface glycoprotein expressed on a subset of normal neuroendocrine cells and natural killer (NK) cells. It is most widely studied as the antibody component of an antibody-drug conjugate (ADC) called lorvotuzumab mertansine (IMGN901). In this ADC, the antibody is conjugated to the potent maytansinoid cytotoxic agent DM1 via a disulfide linker. Upon binding to CD56-positive tumor cells, the ADC is internalized, and DM1 is released intracellularly to disrupt microtubule assembly, leading to cell death. It has been clinically evaluated primarily for the treatment of CD56-positive malignancies, such as small cell lung cancer (SCLC), multiple myeloma, and ovarian cancer.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.